<DOC>
	<DOCNO>NCT00940602</DOCNO>
	<brief_summary>The primary purpose study prospectively assess efficacy safety iron chelation therapy deferasirox compare placebo patient myelodysplastic syndrome ( low/int-1 risk ) transfusional iron overload .</brief_summary>
	<brief_title>Myelodysplastic Syndromes ( MDS ) Event Free Survival With Iron Chelation Therapy Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Males female â‰¥ 18 year age Patients must weigh 35135 kg MDS low int1 risk determine IPSS score confirm bone marrow examination within 6 month prior study entry Ferritin &gt; 1000 mcg/L screen History 15 75 PRBC transfusion Anticipated transfuse least 8 time annually study More 6 month cumulative ironchelation therapy ( daily deferasirox ( Exjade ) deferiprone 5x/week deferosamine ) . intermittent deferoxamine dose association blood transfusion exclusionary regardless duration treatment . More 3 year since patient begin receive regular transfusion ( 2 unit per 8 week 4 unit receive 3 month period ) . Creatinine clearance &lt; 40 ml/min Serum creatinine &gt; 1.5x ULN screen Significant proteinuria : urinary protein/creatinine ratio &gt; 0.5 mg/mg non first void urine sample ECOG performance status &gt; 2 Left ventricular ejection fraction &lt; 50 % ECHO History hospitalization Congestive Heart Failure Systemic disease would prevent study treatment ( uncontrolled hypertension , cardiovascular renal , hepatic ( include ChildPugh Class B C ) metabolic disease ) Hepatitis B C ( HBsAg absences HBsAB HCV Ab positive HCV RNA positive ) History HIV positivity ( ELISA Western blot ) Treatment systemic investigational drug within 4 week topical investigational drug within 7 day study start ALT AST &gt; 3.5 x ULN screen Total bilirubin &gt; 1.5 x ULN screen Diagnosis liver cirrhosis Patient participate another clinical trial receive investigational drug History another malignancy within past five year , exception basal skin carcinoma cervical carcinoma situ completely resect colonic polyp carcinoma situ History noncompliance medical regimen , patient potentially unreliable and/or cooperative Presence surgical medical condition might significantly alter absorption , distribution , metabolism excretion study drug Pregnant intending become pregnant breastfeeding patent History drug alcohol abuse within 12 month prior enrollment . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>TELESTO</keyword>
	<keyword>MDS Study</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Myelodysplastic Syndromes ( low-int-1 risk )</keyword>
</DOC>